CA-THEOREMONE
25.1.2022 00:39:08 CET | Business Wire | Press release
Theorem, LLC, innovation and engineering partner to the Global 1000, today announced that it has rebranded to TheoremOne® following an acquisition of Formula Partners , and launch of its near-shore, pureplay software engineering service, Lemma . The new name positions TheoremOne as the foundation of a family of brands designed to help enterprises build better, more innovative business platforms at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005847/en/
“Our new name positions TheoremOne as the foundation of a family of brands, all inspired by our hypothesis driven model for innovation. Each brand is designed to address the specific needs of our clients at different moments in the lifecycle of enterprise innovation,” said Brady Brim-DeForest, CEO of TheoremOne.
Its newest acquisition, Formula Partners, helps companies create new models for organizational design, continuous improvement, and visionary leadership. Formula Partner’s approach revolves around a modular innovation process called the New Enterprise™, a proprietary model for modern consulting at the nexus of technology and organizational transformation. Formula Partners will become a new independent line of business and will operate under the “Formula Partners” brand.
“We are approaching management consulting from 14 years of implementing technology solutions — giving us a deep understanding of the true benefits (and costs) of making strategic recommendations. We’ve built trust with IT and business leaders through hands-on work, and we’re excited to build even broader strategic relationships through Formula Partners,” said Will Jessup, Head of Services Delivery at TheoremOne.
TheoremOne has also launched a new engineering service called Lemma. Lemma offers pureplay software engineering teams staffed exclusively by nearshore engineering talent. Lemma shares a common engineering DNA with TheoremOne but is designed to deliver engineering capacity as a modular service offering that can be deployed to scale existing teams and initiatives for enterprise and growth stage clients.
“Lemma fills a gap in our offerings that the market has illuminated over the last few years,” said Alex Finnemore, TheoremOne’s Head of Revenue. “It’s a compelling option for clients that have already determined the right way to solve a business problem and need a dedicated technology partner, but want to provide their own product, design, and leadership talent.”
Lemma and Formula Partners will join existing divisions Proof (staff augmentation) and Halmos Ventures (innovation incubation) in rounding out TheoremOne’s end-to-end services stack.
As part of the name change, TheoremOne has released a new company logo and launched a new website at www.theoremone.co .
About TheoremOne®
TheoremOne is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, TheoremOne makes great user experiences accessible to the enterprise. Founded in 2007, TheoremOne’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how TheoremOne enables ambitious leaders to build better software visit www.theoremone.co or follow @TheoremOne
About Formula Partners
Formula Partners is a different kind of management consulting firm — it targets the intersection of technology and organizational transformation, unlocking models for continuous improvement, and enabling visionary leadership within the enterprise. Founded in 2015, Formula Partners is based in Los Angeles. Read more at: www.formula.partners .
About Lemma
Lemma offers pureplay software engineering teams designed to deliver high-quality results at-scale. Clients come to Lemma when they need an injection of fully-managed and modular engineering talent. Learn more about Lemma at: www.thinklemma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005847/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom